India Issues Notices to Nestle, Zydus and Abbott over Child Product Claims
In this article (8)
India’s food safety authority issued formal notices to Nestle India, Zydus Wellness and Abbott Healthcare this week over marketing claims on infant and children’s products that breached national rules.
The enforcement actions rattle an Indian packaged food market valued at more than $100 billion as regulators intensify oversight of nutritional claims.
The move comes shortly after officials proposed prohibiting added sucrose and fructose in foods intended for infants up to six months old.
Evidence Demanded on Formula and Growth Drinks
The Food Safety and Standards Authority of India ordered Nestle India to produce documented evidence supporting promotional assertions about digestive health and immune system benefits. Those claims appear on labels for Lactogen Pro 1 Powder and NAN Excella Pro Stage 1 infant formula.
For Zydus Wellness, the regulator demanded scientific substantiation for marketing claims attached to its Complan children’s beverage brand. Regulators singled out promotional packaging using the slogan “grow taller, faster. Clinically proven 2X growth.”
Enforcement also expanded into digital media distribution channels. The regulator issued separate notices to online influencer Ira Fathima alongside Abbott Healthcare and Nestle India concerning an Instagram reel promoting infant milk substitutes.
Nestle India stated that the authority’s public notice repeated concerns initially raised on September 18 regarding product packaging labels, adding that it had already delivered an extensive formal response to the food regulator.
“Those claims appear on labels for Lactogen Pro 1 Powder and NAN Excella Pro Stage 1 infant formula.”
Abbott took a different position, stating it played no role in the social video campaign. “Abbott does not endorse the claims or representations contained in the content,” a company spokesperson said, adding that the healthcare firm only learned of the material after receiving the authority’s notice and had forwarded that explanation to officials.
Regulatory Pressure Mounts Across FMCG Portfolios
The enforcement notices show Indian authorities closing off the latitude dairy and consumer health brands historically enjoyed when framing products as quasi-medicinal solutions. For multinational operators, children’s nutritional beverages and early stage formulas command premium shelf pricing in modern trade stores and pharmacy chains across tier-one Indian metros.
Pivoting marketing messages from clinical outcomes to simple nutritional content carries commercial risk. When brands cannot claim tangible acceleration in height or immune protection, consumer willingness to pay substantial retail markups over standard milk powders drops quickly.
Packaged goods manufacturers operating in India face a compounding compliance headache. Removing unverified health statements from shelf packaging requires inventory write-downs, packaging redesigns and altered point-of-sale displays across hundreds of thousands of general trade outlets.
Digital influencer campaigns, long used by FMCG marketing teams as an indirect route around tight infant formula promotion laws, now sit squarely within the regulator’s direct enforcement perimeter. Brands can no longer isolate corporate marketing budgets from third-party social media creators promoting their product categories.
Stricter Sugar Rules Set the Stage
The crackdown follows earlier regulatory intervention by the food authority on October 17, when officials proposed an outright ban on adding sucrose and fructose to food products formulated for infants up to six months old.
That regulatory draft landed as authorities stepped up scrutiny of basic formulation standards across processed food segments and advanced plans for mandatory front-of-pack nutritional warning labels.
Regulators will decide whether to mandate product label revisions, levy statutory fines, or order affected product batches removed from retail distribution shelves across the country.
Questions & Answers
Q.Which specific products and promotional claims are Indian regulators targeting?
Which specific products and promotional claims are Indian regulators targeting?
The food safety authority targeted digestive health and immune system assertions on Nestle’s Lactogen Pro 1 and NAN Excella Pro Stage 1 infant formulas. It also demanded scientific substantiation from Zydus Wellness for its Complan slogan claiming clinically proven double growth.
Q.Why has Abbott Healthcare been served with a regulatory notice?
Why has Abbott Healthcare been served with a regulatory notice?
Regulators issued notices to Abbott Healthcare, Nestle India, and online influencer Ira Fathima over an Instagram reel promoting infant milk substitutes. Abbott denied any involvement, stating it played no role in the campaign, did not endorse the content, and only learned of it from officials.
Q.What commercial impact could these enforcement actions have on FMCG brands?
What commercial impact could these enforcement actions have on FMCG brands?
Manufacturers face packaging redesigns, inventory write-downs, and altered retail displays across thousands of outlets. Stripping clinical claims also threatens the premium prices these formulas command over standard milk powders, whilst regulators may impose statutory fines or order product batches to be withdrawn.
Q.What wider regulatory changes has India recently introduced for infant foods?
What wider regulatory changes has India recently introduced for infant foods?
On 17 October, the food authority proposed an outright ban on adding sucrose and fructose to foods intended for infants up to six months old. Officials have also stepped up scrutiny of basic formulation standards and advanced plans for mandatory front-of-pack nutritional warning labels.
Reader pulse
Will stricter label scrutiny dent premium child nutrition sales in India?
24,014 votes so far